Latest Product Development News

WiseTech Global has confirmed its participation in the strategic review process initiated by US-based e2open, amid media speculation of a potential acquisition. While discussions remain preliminary with no certainty of a deal, the move aligns with WiseTech’s ongoing acquisition-driven growth strategy.

BluGlass Limited has launched a $6 million Share Purchase Plan (SPP) offering new shares with attaching options to eligible shareholders, aiming to fund the scale-up of its visible laser production and support ongoing product development.

HITIQ Ltd has successfully completed a $680,000 placement and launched a $2.92 million rights issue, positioning the company to fund its strategic shift towards the consumer market and expand its footprint in the US.

Anagenics Limited reported a cash outflow of $424K for Q3 2025 but maintains robust liquidity with $1.48 million in available funding, supported by a mix of secured and unsecured loans.

BlinkLab Limited has raised A$7.66 million through a well-supported placement to accelerate FDA regulatory trials for its autism and ADHD diagnostic platforms, leveraging its innovative smartphone-based technology.

Anatara Lifesciences has obtained a $400,000 loan advance from a major shareholder group against its estimated R&D tax refund for the first half of FY2025, providing crucial funding to support ongoing clinical trials and product development without immediate capital raising.

8common Limited reported a record Q3 FY25 SaaS and transaction revenue of $1.1 million, alongside a 33% reduction in operational costs, supported by technology upgrades and a $1.5 million financing facility.

Nanoveu Limited has completed its strategic acquisition of EMASS, advancing its foothold in ultra-low-power AI-driven edge computing. The company also strengthened its leadership team and secured additional capital to fuel growth.

OpenLearning Limited reported a 12% year-on-year increase in SaaS annual recurring revenue to $2.364 million in Q1 FY25, driven by AI-powered product adoption and international customer growth. Strategic acquisitions and partnerships are positioning the company for larger contracts and diversified revenue streams.

Hexima Limited reported a stable cash position of $1.55 million at quarter-end, with a modest $87,000 net cash outflow from operations. The biotech company continues to explore strategic opportunities while maintaining a strong funding runway.

Skin Elements Limited advances its natural biotechnology products with ECO-Nurture trials concluding and SuprCuvr disinfectant gaining traction, supported by a successful $656k capital raise.

Cadoux Limited has made significant progress in its High Purity Alumina and Minhub rare earth projects during Q1 2025, advancing engineering studies, securing key contracts, and strengthening ESG initiatives while preparing for commercialisation.